Concordia Healthcare (CHEHF) 31.5100 $CHEHF
Concordia Healthcare Corp. to host second quarter 2014 results conference call
CNW Group - Thu Jul 31, 9:30AM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its second quarter 2014 financial results after market close on Wednesday, August 13, 2014. The Company will subsequently hold a conference call on Thursday, August 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
Concordia Healthcare Corp. Reports Results of Annual General and Special Meeting of Shareholders
CNW Group - Fri Jun 27, 2:46PM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting" were elected as Directors of Concordia. The six (6) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows:
Concordia Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference
CNW Group - Thu Jun 12, 1:00PM CDT
Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET.
Concordia Healthcare Announces Fiscal 2013 Results (May 2013 - December 2013)
PR Newswire - Mon Mar 31, 6:00AM CDT
Company's board approves an annualized US$0.30 dividend -
FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber
PR Newswire - Wed Mar 26, 7:00AM CDT
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber.
Concordia Healthcare Corp. to Host Fiscal 2013 Year-End Results Conference Call
CNW Group - Mon Mar 24, 3:00PM CDT
Concordia Healthcare Corp. ("Concordia" (TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update.
Concordia Healthcare Announces Agreement to Acquire Donnatal®
PR Newswire - Thu Mar 20, 6:30AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS" and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals" .
IIROC Trade Resumption - Concordia Healthcare Corp.
Newsfile Corp - Wed Feb 19, 7:22AM CST
Trading resumes in:
IIROC Trade Halt - Concordia Healthcare Corp.
Newsfile Corp - Tue Feb 18, 2:57PM CST
The following issues have been halted by IIROC:
Concordia Healthcare Corp. begins trading on OTCQX® in U.S.
CNW Group - Thu Jan 30, 8:02AM CST
Announcement follows recent listing on Toronto Stock Exchange
Concordia Healthcare Corp. Begins Trading on OTCQX®
PR Newswire - Thu Jan 30, 7:31AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Concordia Healthcare Corp. ("Concordia" (OTCQX: CHEHF; TSX: CXR), a diverse healthcare company, has been approved to trade on OTCQX®, the best marketplace with qualified companies.
Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
PR Newswire - Mon Jan 13, 7:00AM CST
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle" , a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with the U.S. Food and Drug Administration (the "FDA" under a special protocol assessment (the "SPA" to enroll patients with an advanced form of bile duct cancer in a pivotal Phase 3 clinical trial. There is currently no approved therapy for this cancer type. The SPA is a written agreement between Pinnacle and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application submission. The clinical trial will study the efficacy and safety of photodynamic therapy ("PDT" with PHOTOFRIN® (porfimer sodium) for injection as treatment for unresectable advanced perihilar cholangiocarcinoma ("CCA" Bismuth type III/IV.
Concordia Healthcare Corp. announces Exclusive Distribution Agreement for Ulesfia® with Lachlan Pharma Holdings
PR Newswire - Mon Jan 06, 7:23AM CST
TSX: CXR
Concordia Healthcare Corp. to host second quarter 2014 results conference call
CNW Group - Thu Jul 31, 9:30AM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its second quarter 2014 financial results after market close on Wednesday, August 13, 2014. The Company will subsequently hold a conference call on Thursday, August 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update. Concordia Healthcare Corp. Reports Results of Annual General and Special Meeting of Shareholders
CNW Group - Fri Jun 27, 2:46PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting" were elected as Directors of Concordia. The six (6) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows: Concordia Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference
CNW Group - Thu Jun 12, 1:00PM CDT
Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET.
Concordia Healthcare Announces Fiscal 2013 Results (May 2013 - December 2013)
PR Newswire - Mon Mar 31, 6:00AM CDT
Company's board approves an annualized US$0.30 dividend -
FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber
PR Newswire - Wed Mar 26, 7:00AM CDT
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"
, a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide® DCYL700 Fiber Optic Diffuser Series flexible fiber. Concordia Healthcare Corp. to Host Fiscal 2013 Year-End Results Conference Call
CNW Group - Mon Mar 24, 3:00PM CDT
Concordia Healthcare Corp. ("Concordia"
(TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and Chief Executive Officer, and Mr. Leith Tessy, Chief Financial Officer. A question-and-answer session will follow the corporate update. Concordia Healthcare Announces Agreement to Acquire Donnatal®
PR Newswire - Thu Mar 20, 6:30AM CDT
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS"
and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals" . IIROC Trade Resumption - Concordia Healthcare Corp.
Newsfile Corp - Wed Feb 19, 7:22AM CST
Trading resumes in:
IIROC Trade Halt - Concordia Healthcare Corp.
Newsfile Corp - Tue Feb 18, 2:57PM CST
The following issues have been halted by IIROC:
Concordia Healthcare Corp. begins trading on OTCQX® in U.S.
CNW Group - Thu Jan 30, 8:02AM CST
Announcement follows recent listing on Toronto Stock Exchange
Concordia Healthcare Corp. Begins Trading on OTCQX®
PR Newswire - Thu Jan 30, 7:31AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Concordia Healthcare Corp. ("Concordia"
(OTCQX: CHEHF; TSX: CXR), a diverse healthcare company, has been approved to trade on OTCQX®, the best marketplace with qualified companies. Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
PR Newswire - Mon Jan 13, 7:00AM CST
Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"
, a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with the U.S. Food and Drug Administration (the "FDA" under a special protocol assessment (the "SPA" to enroll patients with an advanced form of bile duct cancer in a pivotal Phase 3 clinical trial. There is currently no approved therapy for this cancer type. The SPA is a written agreement between Pinnacle and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application submission. The clinical trial will study the efficacy and safety of photodynamic therapy ("PDT" with PHOTOFRIN® (porfimer sodium) for injection as treatment for unresectable advanced perihilar cholangiocarcinoma ("CCA" Bismuth type III/IV. Concordia Healthcare Corp. announces Exclusive Distribution Agreement for Ulesfia® with Lachlan Pharma Holdings
PR Newswire - Mon Jan 06, 7:23AM CST
TSX: CXR
